WHY PATIENTS NEED YOU Vaccines is the only place in Pfizer where you can contribute to patients in a way like no other – you can prevent sickness and disease. This is at the heart of what drives us every day and it brings us great #Joy. It is a remarkable time to be part of Pfizer’s US Vaccines business as it expands on its mission of preventing disease and improving public health. RSV Respiratory Syncytial Virus (RSV) is a common respiratory virus that affects the lungs and airways and can be serious, especially for infants. The disease burden of RSV in young children is staggering with virtually all children getting an RSV infection by the time they are two years old. In the United States, up to 600,000 infants experience lower respiratory tract disease (LRTD) due to RSV each year. For children younger than five years old in the U.S., approximately 2.1 million RSV outpatient visits and 58,000 RSV hospitalizations occur each year, and it is a leading cause of hospitalization in children less than one year of age. ABRYSVO ABRYSVO is Pfizer’s bivalent RSV vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age. Following a highly successful first two full seasons season, the team continues strives to further drive vaccine uptake to help protect infants from RSV via maternal immunization during the ACIP recommended season, from Sept. 1 thru Jan. 31. ABRYSVO is the first and only maternal immunization to help protect newborns from RSV immediately at birth through six months. Given a highly competitive and rapidly evolving landscape, success will rely on accelerating vaccination uptake through communicating urgency to protect against RSV, the benefits of Maternal Immunization, robust clinical data, strong recommendations, and establishing Pfizer leadership. The US ABRYSVO Maternal Brand Access secondee will play a key role, working in close collaboration with the Access Lead and Account Management team to protect more infants from RSV within large, organized customers by delivering solutions that help these customers prioritize RSV vaccines for pregnant individuals and members. This colleague must be able to apply a thorough understanding of health systems and payer segments in order to align business priorities that can help drive immunization rates. PREVNAR 20 PEDIATRIC Pfizer’s pediatric pneumococcal vaccine, Prevnar 20, was approved by the FDA in April 2023 and received its ACIP recommendation in June 2023. This vaccine expands serotype coverage to 20 and aims to further protect children from serious pneumococcal disease. This next generation vaccine is a “blockbuster” for the U.S. and is a critical brand within the Vaccines portfolio.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Number of Employees
5,001-10,000 employees